Treatment of refractory and recurrent Clostridium difficile infection.
about
Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated diseaseEvolutionary biology and anthropology suggest biome reconstitution as a necessary approach toward dealing with immune disordersTreatment of Clostridium difficile infection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model.Clostridium difficile infection: guideline-based diagnosis and treatmentPreclinical studies of amixicile, a systemic therapeutic developed for treatment of Clostridium difficile infections that also shows efficacy against Helicobacter pyloriVancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.[Current data and trends on the development of antibiotic resistance of Clostridium difficile].The biodiversity hypothesis and allergic disease: world allergy organization position statement.Epidemiology and Recurrence Rates of Clostridium difficile Infections in Germany: A Secondary Data Analysis.Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection.Identification of a novel zinc metalloprotease through a global analysis of Clostridium difficile extracellular proteinsProceedings of the 2013 A.S.P.E.N. Research workshop: the interface between nutrition and the gut microbiome: implications and applications for human health [corrected].The yin yang of bacterial polysaccharides: lessons learned from B. fragilis PSAChanges in Colonic Bile Acid Composition following Fecal Microbiota Transplantation Are Sufficient to Control Clostridium difficile Germination and Growth.Using a Novel Lysin To Help Control Clostridium difficile InfectionsAssociation of relapse of Clostridium difficile disease with BI/NAP1/027.Fecal transplant in refractory Clostridium difficile colitis.A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in GermanyThe incidence and drug resistance of Clostridium difficile infection in Mainland China: a systematic review and meta-analysis.Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam.Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response.An overview of the diagnosis and management of Clostridium difficile infection.Stool transplants: ready for prime time?Management and prevention of recurrent clostridium difficile infection in patients after total joint arthroplasty: a review.European consensus conference on faecal microbiota transplantation in clinical practice.Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.Kibdelomycin is a potent and selective agent against toxigenic Clostridium difficile.A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection.Novel high-molecular-weight, R-type bacteriocins of Clostridium difficile.Biofilm formation by Clostridium difficile.Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile.The functional vanGCd cluster of Clostridium difficile does not confer vancomycin resistance.Type IV Pili Promote Clostridium difficile Adherence and Persistence in a Mouse Model of Infection.Effect of the Synthetic Bile Salt Analog CamSA on the Hamster Model of Clostridium difficile InfectionExtended duration vancomycin in recurrent infection: a systematic review
P2860
Q26851409-8D781A71-5899-4788-BEE1-E4611A348CACQ30048092-B6835209-3690-4192-BC8F-C79D54CE0297Q30277636-EB1BB505-AED1-4747-9E50-DC0C1B539560Q30316981-19765296-295A-437C-9E92-C0936ADD14CAQ30408277-91BA11F7-5238-4BA4-8069-320B4EF5A033Q30417830-506FDBD8-0F06-45B6-BE7D-BB47F9EF4F14Q30575525-E9F92C5E-308D-4D91-971A-8734E04EE667Q30624202-4535E1C2-06C3-4C35-B2C4-909986F4AECEQ31138398-993159DC-903F-4EBB-A856-7108324C7DCCQ35055851-627A9C8A-FE58-4FD2-B1B4-55C15EDA6945Q35058561-75CE79DF-F56C-41B4-8153-1327DE035250Q35079014-52A4455F-97B4-4FE8-B252-021F1F7BB37CQ35627540-7843C581-1712-4D6D-8F49-9910C08FF2F2Q35899010-CCDC1D58-8FB2-455E-BAAD-074B688FDEE6Q36290571-DDA40253-9A25-4603-B63D-A8CABDB2F5F1Q36414097-1233B45D-F7B4-436B-8609-E76337E3452AQ36647979-B2D11457-FA49-4D35-9439-F94A7E40765BQ37297999-FCFF6015-BFB9-498E-B26F-1D39D90EEF66Q37449268-9633749C-AB57-4198-8D73-2E1AB2389410Q37501021-9259FE93-FC7A-47E6-B295-CE516B239935Q37671489-04A12518-E056-412E-956E-F0DAED2ABFA3Q37992487-E9151696-22F9-4198-9AA5-9A262F01AEC5Q38010065-CE42F2FD-F201-4C1A-8D1A-06CD3169E968Q38097440-EF56C510-0F56-45A5-9362-BFBFAE307057Q38770514-FB32B257-FC52-4C6C-9B25-DECC6D78C1FDQ38904050-6B58993E-E605-474B-A455-AECE76E077A2Q39683062-EDB5B124-2340-4C3B-9E39-BBE933703E60Q40065343-5A330DDA-15E1-4EE7-9126-4B09C2FD41ACQ41576918-595F60BE-B976-490E-8230-9E3005F13519Q41956031-D2A06E82-01B7-4B76-809D-31F8DDC416E3Q42958466-01CBC4B8-CC4E-4D4E-9D44-27E9BF61D533Q50894623-2A9509B6-1D82-4686-AD1F-AF1722732333Q54266191-EC36112A-AA05-401F-B9BC-47DA169AA7F8Q57107809-6C0CDB08-3EC6-4A2C-9411-6AE4AF997CCFQ59138438-8C8022C6-1C45-446D-9D40-E36401B47878
P2860
Treatment of refractory and recurrent Clostridium difficile infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment of refractory and recurrent Clostridium difficile infection.
@en
Treatment of refractory and recurrent Clostridium difficile infection.
@nl
type
label
Treatment of refractory and recurrent Clostridium difficile infection.
@en
Treatment of refractory and recurrent Clostridium difficile infection.
@nl
prefLabel
Treatment of refractory and recurrent Clostridium difficile infection.
@en
Treatment of refractory and recurrent Clostridium difficile infection.
@nl
P2860
P356
P1476
Treatment of refractory and recurrent Clostridium difficile infection.
@en
P2093
Christina M Surawicz
Jacob Alexander
P2860
P2888
P304
P356
10.1038/NRGASTRO.2011.59
P407
P577
2011-04-19T00:00:00Z